The stock of NeoGenomics, Inc. (NASDAQ:NEO) reached all time high today, Nov, 25 and still has $9.75 target or 3.00% above today’s $9.47 share price. This indicates more upside for the $763.81M company. This technical setup was reported by Barchart.com. If the $9.75 PT is reached, the company will be worth $22.91M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 0.64% or $0.06 during the last trading session, hitting $9.47. About 324,940 shares traded hands. NeoGenomics, Inc. (NASDAQ:NEO) has risen 31.42% since April 22, 2016 and is uptrending. It has outperformed by 26.02% the S&P500.
Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on March, 7. They expect $0.02 EPS, 0.00% or $0.00 from last year’s $0.02 per share. NEO’s profit will be $1.61 million for 118.38 P/E if the $0.02 EPS becomes a reality. After $-0.01 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -300.00% EPS growth.
NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage
Out of 8 analysts covering NeoGenomics (NASDAQ:NEO), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. NeoGenomics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The company was maintained on Sunday, September 6 by William Blair. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by TH Capital on Monday, October 26. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Neutral” rating given on Wednesday, July 27 by BTIG Research. The company was maintained on Thursday, September 3 by Roth Capital. Axiom Capital downgraded the stock to “Sell” rating in Wednesday, November 16 report. On Friday, March 11 the stock rating was initiated by Benchmark with “Buy”. The firm has “Overweight” rating given on Tuesday, October 4 by First Analysis. Roth Capital reinitiated NeoGenomics, Inc. (NASDAQ:NEO) rating on Wednesday, May 11. Roth Capital has “Buy” rating and $10 price target.
According to Zacks Investment Research, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.”
Insitutional Activity: The institutional sentiment decreased to 1.25 in 2016 Q2. Its down 0.75, from 2 in 2016Q1. The ratio worsened, as 5 funds sold all NeoGenomics, Inc. shares owned while 34 reduced positions. 36 funds bought stakes while 42 increased positions. They now own 57.99 million shares or 3.94% more from 55.79 million shares in 2016Q1.
Blackrock Advsr Limited Liability Com last reported 0% of its portfolio in the stock. Northpointe Ltd holds 0.45% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 475,747 shares. State Board Of Administration Of Florida Retirement accumulated 0% or 17,810 shares. Tower Rech Capital Lc (Trc) has invested 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Tiaa Cref Mgmt Lc last reported 163,263 shares in the company. The New York-based Goldman Sachs Gp has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Prudential, a New Jersey-based fund reported 22,988 shares. Susquehanna Group Inc Llp accumulated 0% or 49,783 shares. Summit Creek Advsrs Ltd Liability has invested 1.42% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). California State Teachers Retirement System accumulated 0% or 111,530 shares. Voya Management Lc has 25,412 shares for 0% of their US portfolio. Howland Capital Limited Liability Company holds 0.01% or 13,000 shares in its portfolio. Ameriprise Inc has 0% invested in the company for 196,473 shares. The Illinois-based Bard has invested 1.26% in NeoGenomics, Inc. (NASDAQ:NEO). Suntrust Banks last reported 14,287 shares in the company.
Insider Transactions: Since August 19, 2016, the stock had 0 insider buys, and 4 selling transactions for $4.43 million net activity. On Friday, September 23 ALBITAR MAHER sold $23,520 worth of the stock or 2,800 shares.
More important recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Fool.com which released: “Why Neogenomics Inc is Soaring Higher Today” on October 21, 2015, also Marketwatch.com published article titled: “NeoGenomics started at buy with $8 stock price target at Benchmark”, Prnewswire.com published: “NeoGenomics Completes Acquisition of Clarient, Inc.” on December 30, 2015. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) was released by: Prnewswire.com and their article: “NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.” with publication date: October 21, 2015.
NEO Company Profile
NeoGenomics, Inc., incorporated on October 28, 1998, is an operator of a network of cancer-focused genetic testing laboratories. The Firm operates in Laboratory Testing Segment. The Company’s Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Firm has laboratory locations in Ft. Myers and Tampa, Florida; Fresno, Irvine, and West Sacramento, California, and Nashville, Tennessee. The Firm offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues; molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level; Pathology consultation- services provided for clients in which the Company’s pathologists review surgical samples on a consultative basis, and Pharma Services and Clinical Trials-Services supporting pharmaceutical firms in their drug development programs by supporting various clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.